Oportuzumab Monatox

Summary

Oportuzumab Monatox (CHEMBL1743052) is a phase-3 clinical-stage antibody drug conjugate (ATC L01FX16); indicated across 3 conditions including urinary bladder neoplasm and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody drug conjugate
• ATC class: L01FX16
• Indications: 3 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743052
Name	Oportuzumab Monatox
Type	Antibody drug conjugate
Max phase	3
ATC	L01FX16

Also known as: 4D5MOCB-ETA, Oportuzumab monatox, Proxinium, vicinium, Vicinium, Vicineum, XD60E5X7FI, OPORTUZUMAB MONATOX

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
urinary bladder neoplasm	3	MONDO:0004987	EFO:0000294
neoplasm	3	MONDO:0005070	EFO:0000616

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00412776	PHASE2/PHASE3	TERMINATED	Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
NCT02449239	PHASE3	COMPLETED	Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
NCT04859751	PHASE3	UNKNOWN	Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer
NCT00272181	PHASE2	TERMINATED	Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
NCT00462488	PHASE2	COMPLETED	Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
NCT03258593	PHASE1	COMPLETED	Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).